Middle Country Family Medicine

Newsflash

Welcome To
Middle Country Family Medicine Website.

We Hope You Find
The Website Useful

Flu Season is Upon Us....
Don't forget to schedule an
appointment for a flu shot.

A federal panel recommended Wednesday that all children get an annual flu shot, dramatically expanding the pool of people who are urged to ward off the contagious respiratory illness -- and possibly paving the way for a universal flu shot recommendation.

The Advisory Committee on Immunization Practices, which makes recommendations to the Centers for Disease Control and Prevention, expanded the group of children who should get annual flu shots to include healthy children ages 5-18. Previously, the recommendation included only those 6 months to age 5.

Main Menu

Patient Information

Bookmark Us

Contact Information

Dr. Michael Randall
2539 Middle Country Road
Centereach, New York 11720
Tel: (631)580-1740
Fax: (631)580-9155

:: Contact Us ::
:: Directions ::

Plan route with GMaps

Plan your route to us

Visitors Counter

Visitors Counter 1.0.2

Home

Medical News

Medical Newsfeeds

Feed Name	# Articles
Clinical Trials / Drug Trials News	8
American Cancer Society	8
Psych Central	8
Cardiovascular / Cardiology News	8
Cancer / Oncology News	8
Bird Flu / Avian Flu News	8
Allergy News	8
ADHD News	8
Medscape Medical News	8
All DrugInfoZone News	8

Medical News (10)

Medical News Updates

Clinical Trials / Drug Trials News From Medical News Today
Latest Clinical Trials / Drug Trials News From Medical News Today.

Molecular Insight Into The Workings Of A Heart Failure Drug In Clinical Trials
Individuals who have persistent high blood pressure are at increased risks of a number of serious medical conditions, including heart failure. One of the factors that contributes to such heart failure is thickening of the muscle wall of the heart. Such thickening (known as hypertrophy) is a compensatory response of the heart to the high blood pressure.

Prolonged Nevirapine In Breast-Fed Babies Prevents HIV Infection But Leads To Drug-Resistant HIV
Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report. But the investigators highlight the proven superiority of the six-week regimen in preventing mother-to-child HIV transmission in breast-fed infants.

International Copper Industry Defines Role In The Fight Against Hospital Infections
The copper industry is working together to answer one very important question: Can copper and copper alloys (brass and bronze) help curb the spread of bacteria that cause hospital infection? Results of laboratory testing and clinical trials indicate that they can. Scientists from around the world shared their work at the first world congress, 'Copper and Public Health', on copper's role in fighting the bacteria that cause hospital-acquired infections.

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor Of CK2
Cylene Pharmaceuticals announced that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma. The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and PK properties of CX-4945 and to select the appropriate dose for Phase II trials.

Phase III Trial Begins For GAMMAGARD LIQUID Plus RHuPH20 In Primary Immunodeficiency Patients
Baxter International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID).

Prism Pharmaceuticals Receives FDA Approval Of NEXTERONE(R) For Life Threatening Ventricular Fibrillation And Ventricular Tachycardia
Prism Pharmaceuticals announced that the U.S. Food & Drug Administration (FDA) has approved the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone(R) Intravenous.

Immutep Announces Positive Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
Immutep S.A. announced today interim results from its ongoing Phase I/II chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 was administered the day after weekly paclitaxel for six months. The interim results show a clinical response rate of 50 per cent compared to 25 per cent with paclitaxel alone. In addition, a robust immune response was observed in clinically-responding patients.

Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting
A study published today in the Journal of Clinical Oncology demonstrates that the addition of Erbitux® (cetuximab) to standard oxaliplatin-based chemotherapy (FOLFOX-4) in previously untreated metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors results in significantly higher efficacy than chemotherapy alone.